Search results for "Lupus anticoagulant"

showing 10 items of 15 documents

Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weig…

2008

ABSTRACT Case report A 69-year-old woman with splenic marginal-zone lymphoma was admitted with progressive abdominal pain and splenomegaly as the suspected cause of pain. Rituximab treatment (375 mg/m 2 ) had been initiated on the day of admission. Abdominal computerized tomography revealed splenic infarction. Laboratory tests showed elevation of liver enzymes and creatinine, low platelet count, prolonged partial thromboplastin time, and lupus anticoagulant positivity. The diagnosis of catastrophic antiphospholipid antibody syndrome was made. Weight-adjusted low-molecular weight heparin therapy was initiated. Freedom from symptoms and normalization of liver enzymes and creatinine occurred w…

Bendamustinemedicine.medical_specialtyLymphoma B-Cellmedicine.drug_classLow molecular weight heparinAntineoplastic AgentsGastroenterologyAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineBendamustine HydrochlorideHumansMedicineSplenic marginal zone lymphomaAgedLupus anticoagulantbusiness.industrySplenic NeoplasmsAnticoagulantAntibodies MonoclonalAnticoagulantsGeneral MedicineHeparinHeparin Low-Molecular-WeightAntiphospholipid Syndromemedicine.diseaseSurgerySplenic infarctionNitrogen Mustard CompoundsFemaleRituximabRituximabbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection.

2005

Abstract Objective To investigate the close association between different antiphospholipid antibodies (aPL) caused by infection and their appearance together with a prolonged activated partial thromboplastin time (aPTT). Methods Sera from 122 children were evaluated in this study. Thirty-seven children with mild to medium prolonged aPTT (>37.2 s) and elevated C-reactive protein (CRP) levels during various forms of infections (group 2), 18 children without infections (group 3) but with mild to medium prolonged aPTT and 13 children with infections (group 4) and with elevated CRP-level as well as a control group (group 1) of 54 patients without any infection and normal aPTT and negative CRP le…

MaleAdolescentFeverImmunologyInfectionsImmunoglobulin Gchemistry.chemical_compoundCardiolipinmedicineImmunology and AllergyHumansChildLupus anticoagulantbiologymedicine.diagnostic_testbusiness.industryC-reactive proteinInfantHematologyPhosphatidylserinemedicine.diseaseC-Reactive ProteinchemistryImmunoglobulin MImmunoglobulin MChild PreschoolImmunoglobulin GImmunologybiology.proteinAntibodies AntiphospholipidFemalePartial Thromboplastin TimeAntibodybusinessPartial thromboplastin timeImmunobiology
researchProduct

Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different

1998

In order to clarify the coagulation profile accompanying ischemic stroke, which may have implications on therapeutic strategies, we performed a prospective study to evaluate the hemostatic parameters in the first 24 h after the onset of cortical atherothrombotic infarct and lacunar infarction. Twenty-seven patients with cortical atherothrombotic infarction and 27 patients with lacunar infarction, diagnosed on clinical and CT-scan criteria, had blood samples taken within the first 24 h after onset of the stroke, and before anticoagulant treatment had been started. Levels of fibrinogen, von Willebrand factor, D-dimers, prothrombin factors 1 + 2, anti-thrombin III, and C-protein and S-proteins…

Malemedicine.medical_specialtyFibrinogenBrain IschemiaVon Willebrand factorInternal medicinemedicineHumansProspective Studiescardiovascular diseasesProspective cohort studyStrokeAgedBlood coagulation testAged 80 and overHemostasisLupus anticoagulantbiologybusiness.industryThrombosisCerebral InfarctionGeneral MedicineMiddle Agedmedicine.diseaseCerebrovascular DisordersDementia Multi-InfarctNeurologyCoagulationHemostasisbiology.proteinCardiologyFemaleBlood Coagulation TestsNeurology (clinical)businessmedicine.drugNeurological Research
researchProduct

Thrombotic events in systemic lupus erythematosus. Its association with acquired and inherited thrombophilic defects.

2008

Systemic lupus erythematosus (SLE) is characterised by increased venous and arterial thrombotic risk. Although antiphospholipid antibodies (APAs) have been shown to be related with thrombotic tendency in these patients, in more than 40% of them, thrombosis occurs without the presence of such antibodies. We analysed the association of venous and arterial thrombotic events with acquired (anticardiolipin antibodies (ACAs) and lupus anticoagulant (LA)) and inherited (antithrombin (AT), protein C (PC), protein S (PS) deficiencies, factor V Leiden and the prothrombin G20210A mutation), thrombophilic risk factors in 86 SLE patients and 89 healthy controls. Patients showed a higher significant perc…

AdultMalemedicine.medical_specialtyPhysiologyGastroenterologyProtein SRisk FactorsPhysiology (medical)Internal medicinemedicineFactor V LeidenHumansLupus Erythematosus SystemicRisk factorLupus anticoagulantbiologybusiness.industryAntithrombinThrombosisHematologyBlood ProteinsMiddle Agedmedicine.diseaseThrombosisVenous thrombosisAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyMutationbiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessProtein Cmedicine.drugClinical hemorheology and microcirculation
researchProduct

Antiphospholipid syndrome in obstetrics.

2003

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thromb…

Adultmedicine.medical_specialtyAbortion HabitualPlacental insufficiency030204 cardiovascular system & hematologyGastroenterologyPreeclampsia03 medical and health sciences0302 clinical medicinePre-Eclampsiaimmune system diseasesAntiphospholipid syndromePregnancyInternal medicinemedicinePrevalenceHumansThrombophiliaAnnexin A5030203 arthritis & rheumatologyLupus anticoagulantAspirinPregnancyFetal Growth RetardationAspirinbusiness.industryHeparinStandard treatmentInfant NewbornAnticoagulantsImmunoglobulins IntravenousHematologyGeneral MedicineHeparinmedicine.diseaseAntiphospholipid SyndromePlacental InsufficiencyThrombocytopeniaAbortion SpontaneousPregnancy ComplicationsAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyPrednisoneFemalebusinessImmunity Maternally-AcquiredImmunosuppressive Agentsmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?

2021

Antiphospholipid syndrome (APS) is frequently associated with thrombocytopenia, in most cases mild and in the absence of major bleedings. In some patients with a confirmed APS diagnosis, secondary immune thrombocytopenia (ITP) may lead to severe thrombocytopenia with consequent major bleeding. At the same time, the presence of antiphospholipid antibodies (aPL) in patients with a diagnosis of primary ITP has been reported in several studies, although with some specific characteristics especially related to the variety of antigenic targets. Even though it does not enter the APS defining criteria, thrombocytopenia should be regarded as a warning sign of a “high risk” APS and thus thoroughly ev…

Pediatricsmedicine.medical_specialtyQH301-705.5medicine.drug_classMedicine (miscellaneous)thrombocytopeniaReviewGeneral Biochemistry Genetics and Molecular BiologyAntigenimmune system diseasesAntiphospholipid syndromehemic and lymphatic diseasesmedicineBiology (General)Antiphospholipid antibodies Antiphospholipid syndrome Immune thrombocytopenia Lupus anticoagulant ThrombocytopeniaLupus anticoagulantbiologybusiness.industryAnticoagulantantiphospholipid antibodiesmedicine.diseaseThrombosisImmune thrombocytopeniaVenous thrombosislupus anticoagulantimmune thrombocytopeniabiology.proteinAntibodybusinessAntiphospholipid antibodieantiphospholipid syndromeBiomedicines
researchProduct

The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.

2007

The role of thrombophilia and thyroid autoimmunity in unexplained infertility (UI), implantation failure (IF) and recurrent spontaneous abortion (RSA) is controversial and poorly understood.From March, 2004 to January, 2007, 119 women were prospectively included: 32 oocyte donors, 31 patients with UI, 26 with IF and 30 with RSA. The IF and RSA groups presented normal preimplantation genetic screening. Protein C, protein S, antithrombin III, lupus anticoagulant, activated protein C resistance (APCR), immunoglobulin M and G anticardiolipin antibodies, homocystine, Factor V Leiden, prothrombin G20210A mutation, methylentetrahydrofolate reductase C677T mutation, thyroid-stimulating hormone (TSH…

Adultendocrine systemmedicine.medical_specialtyAbortion Habitualmedicine.medical_treatmentThyroid GlandAutoimmunityThrombophiliaGastroenterologyIodide PeroxidaseThyroglobulinAntiphospholipid syndromeInternal medicinemedicineFactor V LeidenPrevalenceHumansThrombophiliaEmbryo ImplantationProspective StudiesUnexplained infertilityActivated Protein C ResistanceAutoantibodiesLupus anticoagulantbusiness.industryRehabilitationThyroidObstetrics and Gynecologymedicine.diseaseEndocrinologymedicine.anatomical_structureReproductive MedicineLupus Coagulation InhibitorThyroglobulinFemaleActivated protein C resistancebusinessInfertility FemaleHuman reproduction (Oxford, England)
researchProduct

Neuroprotective effect of Fn14 deficiency is associated with induction of the granulocyte-colony stimulating factor (G-CSF) pathway in experimental s…

2010

Using a transgenic mouse model of ischemic stroke we checked for a possible interaction of antiphospholipid antibodies (aPL) which often cause thromboses as well as central nervous system (CNS) involvement under non-thrombotic conditions and the TWEAK/Fn14 pathway known to be adversely involved in inflammatory and ischemic brain disease. After 7 days, infarct volumes were reduced in Fn14 deficient mice and were further decreased by aPL treatment. This was associated with strongest increase of the endogenous neuroprotective G-CSF/G-CSF receptor system. This unexpected beneficial action of aPL is an example for a non-thrombogenic action and the double-edged nature of aPL.

MaleGenetically modified mouseImmunologyMice TransgenicBiologyNeuroprotectionReceptors Tumor Necrosis FactorBrain IschemiaMiceRandom AllocationTissue factorimmune system diseasesAntiphospholipid syndromeGranulocyte Colony-Stimulating FactormedicineAnimalsHumansImmunology and AllergyneoplasmsStrokeLupus anticoagulantmedicine.diseaseMice Inbred C57BLDisease Models AnimalNeurologyTWEAK ReceptorReceptors Granulocyte Colony-Stimulating FactorImmunologyAntibodies AntiphospholipidTumor necrosis factor alphaNeurology (clinical)Inflammation MediatorsGranulocyte colony-stimulating factor receptorSignal TransductionJournal of Neuroimmunology
researchProduct

Short-term therapy for recurrent abortion using intravenous immunoglobulins: Results of a double-blind placebo-controlled Italian study

1997

It is still unclear whether i.v. immunoglobulins (Ig) can facilitate the reproductive prognosis of women who have suffered recurrent pregnancy loss. We report the results of a multicentre placebo-controlled study on the effect of Ig administration on pregnancy outcome in 46 women who had suffered at least three recurrent miscarriages. All were screened to exclude chromosomal or Müllerian abnormalities, the presence of antinuclear antibodies, lupus anticoagulant (LA) or elevated titres of anticardiolipin antibodies which may have revealed an underlying autoimmune problem. To avoid a selection bias towards ongoing pregnancies, i.v. Ig or placebo were administered between weeks 5 and 7 of gest…

AdultAbortion Habitualmedicine.medical_specialtyAnti-nuclear antibodyAbortionPlacebolaw.inventionDouble-Blind MethodRandomized controlled trialPregnancylawAntiphospholipid syndromemedicineHumansLupus anticoagulantPregnancyObstetricsbusiness.industryRehabilitationPregnancy OutcomeImmunoglobulins IntravenousObstetrics and Gynecologymedicine.diseaseSurgeryItalyReproductive MedicineGestationFemalebusiness
researchProduct

A new pro-thrombotic mechanism of neutrophil extracellular traps in antiphospholipid syndrome: impact on activated protein C resistance

2021

Abstract Objectives In APS, precise evaluation of thrombotic risk is a major challenge. Different players, such as activated protein C (APC) resistance or neutrophil extracellular traps (NETs) contribute to the risk of thrombosis. Nevertheless, no study has investigated the interaction between these actors. The main objective of this study was to investigate the relation between NETs and APC resistance. Methods We designed a cross-sectional study including APS/antiphospholipid antibodies (aPL) patients and patients with autoimmune diseases (AID). We performed thrombin generation tests without and with APC to determine APC resistance. To evaluate circulating NETs, we measured plasma levels o…

Lupus anticoagulantbiologybusiness.industryThrombosisNeutrophil extracellular trapsAntiphospholipid Syndromemedicine.diseaseExtracellular TrapsThrombosisCross-Sectional StudiesRheumatologyAntiphospholipid syndromeImmunologyAntithromboticmedicinebiology.proteinHumansPharmacology (medical)AntibodyActivated protein C resistancebusinessProtein CActivated Protein C Resistancemedicine.drugRheumatology
researchProduct